Parvinder K. Aley

University of Oxford — United Kingdom

Medicine · Health Sciences

39h-index19.9kcitations103works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(57), COVID-19 Clinical Research Studies(37), Vaccine Coverage and Hesitancy(19), Calcium signaling and nucleotide metabolism(11), Immunotherapy and Immune Responses(10)

Publications102 total

Innate antiviral readiness drives the expansion of protective T stem cell memory against influenza
2025Open Access
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial
Journal of Infection·2025Open Access
Pre-existing immunity levels are essential for expanding long-lived influenza-specific memory CD8 T-cells following vaccination 2634
The Journal of Immunology·2025Open Access
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines
Science Immunology·2025· 4 citedOpen Access
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial
Journal of Infection·2025Open Access
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)
Vaccine·2025Open Access
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Mayo Clinic Proceedings Innovations Quality & Outcomes·2025Open Access
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
Journal of Infection·2025Open Access
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Vaccine·2024Open Access
Pneumococcal Carriage and Disease in Adults in England, 2011–2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities
The Journal of Infectious Diseases·2024· 10 citedOpen Access
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
The Lancet Microbe·2024· 6 citedOpen Access
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
iScience·2023· 6 citedOpen Access
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
The Lancet Microbe·2023· 9 citedOpen Access
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
Human Vaccines & Immunotherapeutics·2023· 3 citedOpen Access
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
Journal of Infection·2023· 10 citedOpen Access
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
Journal of Infection·2023· 37 citedOpen Access
Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]
Journal of Infection·2023· 1 citedOpen Access
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants
Vaccine·2023· 13 citedOpen Access
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines
Journal of Infection·2023· 17 citedOpen Access
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Clinical & Experimental Immunology·2023· 13 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Teresa Lambe(34), Andrew J. Pollard(27), Yama F Mujadidi(25), Matthew D. Snape(24), Maheshi Ramasamy(23), Sarah C. Gilbert(22), Hannah Robinson(21), Emma Plested(20), Elizabeth Clutterbuck(20), Sagida Bibi(19), Daniel Jenkin(19), Angela M. Minassian(19), Merryn Voysey(19), Saul N. Faust(18), Pedro M. Folegatti(17), Anna L. Goodman(16), Christopher Green(16), Adrian V. S. Hill(16), Christina Dold(16), Katie Ewer(15)